BHC Bausch Health Companies Inc.

15.54
+0.66  (+4%)
Previous Close 14.88
Open 14.87
52 Week Low 11.15
52 Week High 31.97
Market Cap $5,516,593,706
Shares 354,951,415
Float 311,759,657
Enterprise Value $24,627,598,216
Volume 5,066,306
Av. Daily Volume 4,571,437
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
IDP-124
Atopic Dermatitis
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
IDP-120
Acne
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
XIPERE (Suprachoroidal CLS-TA)
Macular edema associated with non-infectious uveitis
NDA Filing
NDA Filing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
EM-100
Allergic conjunctivitis
Approved
Approved
FDA approval announced September 25, 2020.
IDP-126
Acne
Phase 3
Phase 3
Phase 3 trial ongoing.
Rifaximin
Overt hepatic encephalopathy
Phase 2
Phase 2
Phase 2 data met primary endpoint - March 31, 2020.
Rifaximin
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial to commence 3Q 2021.
Rifaximin
Small intestinal bacterial overgrowth (SIBO)
Phase 2
Phase 2
Phase 2 trial planned.
Amiselimod S1P6 Modulator
Phase 2
Phase 2
Phase 2 trial to commence 2H 2020.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
Approved
Approved
FDA approval announced April 25, 2019.
IDP-123
Acne
Approved
Approved
FDA Approval announced December 19, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approved
Approved
FDA approval announced February 25, 2019.
IDP-122
Psoriasis
Approved
Approved
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-121
Acne
Approved
Approved
FDA Approval announced August 24, 2018.
ULTRA - 7 days
Contact lens
Approved
Approved
Approval announced March 2, 2018.
Plenvu (NER1006)
Bowel cleansing
Approved
Approved
Approval announced May 7, 2018.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
Approved
Approved
Approval announced November 2, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
Approved
Approved
Approval announced December 22, 2017.
Brodalumab
Psoriasis
Approved
Approved
Approved February 15, 2017.

Latest News

  1. LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ:ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander, which is one of the eye symptoms that affects approximately 80 percent of people with allergies.[1] Preservatives commonly used in eye drops can cause allergic reactions in…

    LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ:ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Alaway® Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100), as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander, which is one of the eye symptoms that affects approximately 80 percent of people with allergies.[1] Preservatives commonly used in eye drops can cause allergic reactions in some people that can lead to redness, irritation, itching or tearing.[2],[3] 

    "We're excited to add Alaway Preservative Free – the first and only OTC preservative-free formulation eye drop of its kind – to our existing Bausch + Lomb Consumer Health Care portfolio. Alaway Preservative Free can provide up to 12 hours of relief for people suffering from itchy eyes due to certain eye allergies," said Joe Gordon, U.S. president, Bausch + Lomb. "We expect Alaway Preservative Free will be available for purchase in the Spring of 2021 at major retailers in time for the start of allergy season." 

    Alaway® Preservative Free is indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander in adults and children 3 years of age and older. It is formulated to relieve eye itch within minutes and can provide up to 12 hours of eye itch relief with one dose.

    "We are pleased the FDA has approved Alaway Preservative Free, and we look forward to collaborating with Bausch + Lomb to bring this unique eye drop to patients suffering from itchy eyes associated with eye allergies," said Sean Brynjelsen, CEO, Eton Pharmaceuticals.

    An affiliate of Bausch Health acquired the U.S. rights to Alaway Preservative Free from Eton in 2019.

    About Eton Pharmaceuticals

    Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products. Eton is primarily focused on hospital injectable and pediatric rare disease products. The company's first commercial product, Biorphen, is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019. The company's lead pediatric product is the orphan drug Alkindi® Sprinkle, which is currently under review with the FDA. For more information, visit www.etonpharma.com.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.  

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    Alaway is a trademark of Bausch & Lomb Incorporated or its affiliates.

    © 2020 Bausch & Lomb Incorporated or its affiliates.

    APF.0015.USA.20

    [1] The 2018 U.S. Study of Allergies, Multi-sponsor Surveys, Inc. February 2018.

    [2] Baudouin C. The Ocular Surface in Glaucoma, Cornea, Volume 28, Number 9, Suppl. 1, October 2009.

    [3] Baudouin C. Allergic reaction to topical eye drops. Curr Opin Allergy Clin Immunol. 2005;5:459–63.

    Eton Investor and Media Contact:

    David Krempa



    612-387-3740

    Bausch Health Investor Contact:

    Arthur Shannon 

     

    (514) 856-855

    (877) 281-6642 (toll free)

    Bausch Health Media Contact: 

    Lainie Keller

     

    (908) 927-1198

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-approves-bausch--lomb-alaway-preservative-free-ketotifen-fumarate-ophthalmic-solution-0-035-301138158.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
    • PrVYZULTA® Added Under Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Federal Non-Insured Health Benefits (NIHB) Plans

    LAVAL, QC, Sept. 24, 2020 /CNW Telbec/ - Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. (NYSE:BHC) (TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador and as part of the federal Non-Insured Health Benefits (NIHB). 

    • PrVYZULTA® Added Under Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Federal Non-Insured Health Benefits (NIHB) Plans

    LAVAL, QC, Sept. 24, 2020 /CNW Telbec/ - Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. (NYSE:BHC) (TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador and as part of the federal Non-Insured Health Benefits (NIHB). 

    These provinces join Ontario, which made VYZULTA available to patients in December 2019.ii

    Affecting over 400,000 Canadians, glaucoma is a disease of the optic nerve and the leading cause of blindness in North America.iii

    "We are pleased that a growing number of provinces and the federal government recognize the impact of glaucoma on patients and the health care system and are increasing access to VYZULTA, a new option that can help patients manage this potentially life-altering condition and possibly preserve eyesight," said Richard Lajoie, President and General Manager of Bausch Health, Canada. "Bausch + Lomb is very proud of the part we play in helping Canadians live better by enabling them to see better with our products."

    VYZULTA has a dual mechanism of action for lowering intraocular pressure by increasing outflow of aqueous humor through both uveoscleral and trabecular meshwork routes.i VYZULTA  is to be administered once daily.

    "VYZULTA is the first molecule introduced into Canada in approximately 20 years with a unique mode of action for reducing eye pressure, and is an important advancement in the medical management of glaucoma because it offers a novel therapeutic option for our patients," said Dr. David Yan, Ophthalmologist-in-Chief, Sinai Health System. 

    For Canadians, glaucoma is one of the leading causes of irreversible blindness.iv Glaucoma is defined as a group of eye diseases that slowly and progressively affect the optic nerve,v which can lead to irreversible vision loss. Open-angle glaucoma is the most common form of the disease and is associated with elevated pressure caused by a backup of fluid in the eye.vi

    "The governments of Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Newfoundland and Labrador, and the federal government, through the Non-Insured Health Benefits program are showing their commitment to advancing the standard of care for glaucoma patients by making Vyzulta available to patients on public formularies," said Doug Earle, President & CEO, Fighting Blindness Canada. "On behalf of the constituents of Fighting Blindness Canada, I am heartened to see that people in these provinces and jurisdictions living with open-angle glaucoma now have access to another treatment option that they can discuss with their optometrist or ophthalmologist."

    VYZULTA received its Notice of Compliance (NOC) from Health Canada on Dec. 27, 2018 and is currently covered by most private insurance plans in Canada.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.ca.

    About Bausch Health 

    Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

    In Canada, our areas of focus include eye health, dermatology and cardio metabolic. More information can be found at www.bauschhealth.ca

    ______________________________

    i 

    PrVyzulta® Product Monograph, dated December 27, 2018.

    ii 

    Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes – December 2019 Effective December 20, 2019,p.5; http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20191213.pdf

    iii 

    CADTH Common Drug Review - Patient Input. Latanorpostene Bunod (Vyzulta). December 12, 2018. https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0590%20Vyzulta%20-%20Patient%20Group%20Input_January%208%2C%202019.pdf Accessed: September 18, 2020

    iv  

    Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262v Horton JC. Disorders of the Eye. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill Education; 2015.

    vi 

    Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee; Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44 Suppl 1:S7-S93. 

     

    SOURCE Bausch + Lomb Canada

    Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2020/24/c2903.html

    View Full Article Hide Full Article
  2. Recent Access Wins Also Make VYZULTA Available To More Americans and Canadians

    SOPHIA ANTIPOLIS, France and LAVAL, Quebec, Sept. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval in Ukraine, bringing the total number of countries where VYZULTA is approved to market to seven. These countries include Argentina, Canada, Hong Kong, Mexico, Taiwan, Ukraine and the United States.

    In Canada, VYZULTA also now has public drug reimbursement in the…

    Recent Access Wins Also Make VYZULTA Available To More Americans and Canadians

    SOPHIA ANTIPOLIS, France and LAVAL, Quebec, Sept. 24, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval in Ukraine, bringing the total number of countries where VYZULTA is approved to market to seven. These countries include Argentina, Canada, Hong Kong, Mexico, Taiwan, Ukraine and the United States.

    In Canada, VYZULTA also now has public drug reimbursement in the provinces of Alberta, Saskatchewan, Manitoba, New Brunswick, Newfoundland and Labrador and Nova Scotia, and as part of the federal Non-Insured Health Benefits. These provinces join Ontario, which made VYZULTA available to patients in December 2019.

    Additionally, due to a recent formulary change in the United States, Medicare Part D coverage of VYZULTA increased in the United States to approximately 45% up from approximately 30%1 earlier this year. VYZULTA is indicated in the United States for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.2

    "We are committed to continuing to secure additional regulatory approvals in multiple markets around the world, as well as working to increase access and availability for VYZULTA, because it is an important treatment option for people suffering from glaucoma," said Joseph C. Papa, chairman and CEO, Bausch Health.

    Indication and Important Safety Information about VYZULTA

    INDICATION AND USAGE

    VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    IMPORTANT SAFETY INFORMATION

    • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
    • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
    • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
    • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
    • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
    • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
    • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

    Please see full prescribing information here.

    About Nicox

    Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma.  The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch & Lomb Incorporated and ZERVIATE™ in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and Southeast Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

    About Bausch + Lomb

    Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.  

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Nicox Forward-looking Statements

    The information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which are available on Nicox's website (www.nicox.com).

    Bausch Health Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    VYZULTA is a trademark of Bausch & Lomb Incorporated or its affiliates.

    © 2020 Bausch & Lomb Incorporated or its affiliates.

    VYZ.0198.USA.20

    1 Managed Markets Insight & Technology, LLC database as of September 2020

    2 VYZULTA® [prescribing information]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2019.

    Nicox Investors & Media Contact:

    Gavin Spencer



    +33 (0)4 97 24 53 00

    Mary-Ann Chang



    +44 7483 284 853

    Nicox Media France Contact:

    Sophie Baumont



    +33 6 27 74 74 49

    Investor Contact:

    Art Shannon



    (514) 856-3855

    (877) 281-6642 (toll free)

    Media Contact:

    Lainie Keller



    (908) 927-1198

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-announces-vyzulta-latanoprostene-bunod-ophthalmic-solution-0-024-is-now-approved-in-seven-countries-301137118.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  3. Includes Special Report on Global COVID-19 Response and Commitment to Diversity & Inclusion

    LAVAL, QC, Sept. 23, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today released its annual Corporate Social Responsibility (CSR) Report, highlighting the Company's ongoing commitment to responsible, ethical and sustainable operations in 2019. In addition to outlining initiatives and key performance indicators in 2019, the report features an early look at 2020 efforts, including the Company's COVID-19 response efforts in the first half of 2020 and its Diversity & Inclusion (D&I) initiatives.

    "Now more than ever, we recognize the increased importance of corporate citizenship in creating an environment where our employees, our customers, our partners and our communities can thrive," said Joseph C. Papa, chairman and CEO, Bausch Health. "As we continue to improve sustainability and raise the bar on our ethical, social and operational standards, we are furthering our mission to improve lives and advance global health."

    The 2019 CSR report also includes other global efforts in the Company's five key commitment areas: operate with integrity; respect the environment; advance global health and patient care; improve communities; and support employee growth and well-being. Additionally, the report includes the highlights of charitable giving efforts directed by the Bausch Foundation, as detailed in the Bausch Foundation Inaugural Activity Report released earlier this month.

    2019 CSR highlights include:

    • Reductions in energy usage, water usage, waste production and carbon emissions at Bausch Health facilities
      • Establishment of Energy Efficiency Group (EEG) to analyze and improve energy consumption globally
      • Installation of new nitrogen-generating plant in Waterford, Ireland, reducing future carbon dioxide emissions by nearly 200 tons per year
    • Collaborations, financial contributions and product donations to global charitable health organizations and patient advocacy groups
    • Continued commitment to patient access and responsible pricing, including that the average annual price increase for branded prescription products would be set at no greater than single digits
    • Continuing to support provider education, research grants and charitable organizations devoted to improving patient care and quality of life, and advancing the safety and effectiveness of healthcare products

    The full report can be viewed in the Responsibility section of Bausch Health's website at https://www.bauschhealth.com/responsibility.

    About Bausch Health 

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements  

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

    Investor Contact:

    Media Contact:

    Arthur Shannon

    Lainie Keller

     

    (514) 856-3855

    (908) 927-1198

    (877) 281-6642 (toll free)



     

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-releases-annual-corporate-social-responsibility-report-301136096.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
  4. Salix Will Maintain Market Exclusivity for XIFAXAN® (rifaximin) 200 mg and 550 mg Tablets Until 20281

    LAVAL, QC, Sept. 22, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its gastroenterology business, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, together with Salix's licensor Alfasigma SpA (collectively the "Salix Parties"), have agreed to resolve outstanding intellectual property disputes with Sun Pharmaceutical Industries Ltd. ("Sun") regarding XIFAXAN® (rifaximin) 200 mg and 550 mg tablets. The Salix Parties will grant Sun a non-exclusive license…

    Salix Will Maintain Market Exclusivity for XIFAXAN® (rifaximin) 200 mg and 550 mg Tablets Until 20281

    LAVAL, QC, Sept. 22, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its gastroenterology business, Salix Pharmaceuticals ("Salix"), which is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, together with Salix's licensor Alfasigma SpA (collectively the "Salix Parties"), have agreed to resolve outstanding intellectual property disputes with Sun Pharmaceutical Industries Ltd. ("Sun") regarding XIFAXAN® (rifaximin) 200 mg and 550 mg tablets. The Salix Parties will grant Sun a non-exclusive license effective Jan. 1, 2028 to its intellectual property relating to XIFAXAN 200 mg and 550 mg tablets in the United States.

    In April 2019, Bausch Health filed a lawsuit against Sun following receipt of a Notice of Paragraph IV Certification relating to XIFXAN 200 mg tablets. Additionally, Bausch Health received a Notice of Paragraph IV Certification from Sun relating to XIFAXAN 550 mg tablets on Aug. 10, 2020.

    "Resolving these matters with Sun is another testament to the strength of the XIFAXAN intellectual property," said Joseph C. Papa, chairman and CEO, Bausch Health. "We will continue to defend our intellectual property protecting XIFAXAN, and we will continue to invest in the research and development of new indications and formulations for rifaximin that can potentially benefit more patients."

    "Alfasigma is satisfied with the resolution," said Pier Vincenzo Colli, CEO of Alfasigma. "In the interest of patients and customers, our company is committed to using any efforts to protect its intellectual property covering XIFAXAN."

    Sun acknowledges the validity of the licensed patents with respect to the two XIFAXAN products. Final patent expiry on XIFAXAN 200 mg and 550 mg tablets are July and October 2029, respectively.

    Under the terms of the agreement, beginning Jan. 1, 20281 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of XIFAXAN 200 mg and  550 mg tablets, should it receive approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application.

    Litigation between the parties related to XIFAXAN will be dismissed, and all intellectual Property protecting XIFAXAN remains intact. Bausch Health and Alfasigma remain confident in the strength of the XIFAXAN patents, and they will continue to vigorously defend their intellectual property. XIFAXAN 200 mg and 550 mg tablets are collectively protected by 26 patents covering the composition of matter and the use of XIFAXAN listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.

    Bausch Health agreed to resolve outstanding intellectual property litigation with Actavis Laboratories FL, Inc. ("Actavis") and Sandoz Inc. ("Sandoz") regarding XIFAXAN 550 mg tablets In September 2018 and in May 2020, respectively. Under the terms of the agreements, the Salix Parties will grant Actavis and Sandoz non-exclusive licenses effective Jan. 1, 20282 to the Salix Parties' intellectual property relating to XIFAXAN 550 mg tablets in the United States.

    About Alfasigma 

    Alfasigma, one of the leading Italian pharmaceutical companies, is present in over 90 countries, through distributors and subsidiaries and has a workforce of around 3,000 people, R&D laboratories, and 5 production plants. In Italy, Alfasigma is a leader in the market for prescription products where, in addition to the strong focus on gastrointestinal, it is present in many primary care therapeutic areas. Alfasigma also produces and markets self-medication products, nutraceuticals and food supplements. More information is available at the Alfasigma website at: http://www.alfasigma.com/en.

    About Bausch Health

    Bausch Health Companies Inc. (TSX:BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

    Forward-looking Statements

    This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

















    1 

    Sun will be able to begin marketing the medicine earlier if another generic rifaximin product is granted approval and starts selling or distributing such generic rifaximin product before Jan. 1, 2028. On Feb. 17, 2020, the Salix Parties received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals, Inc. relating to XIFAXAN tablets, 550 mg; and filed suit against Norwich on March 26, 2020, which remains pending.





    2 

    Actavis and Sandoz will be able to begin marketing the medicine earlier if another generic rifaximin product is granted approval and starts selling or distributing such generic rifaximin product before Jan. 1, 2028.

     

    Investor Contact:         







    Media Contact:

    Arthur Shannon   







    Lainie Keller

      







    (514) 856-3855       







    (908) 927-1198

    (877) 281-6642 (toll free)    









     

    Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-and-alfasigma-announce-resolution-of-xifaxan-intellectual-property-litigation-301135108.html

    SOURCE Bausch Health Companies Inc.

    View Full Article Hide Full Article
View All Bausch Health Companies Inc. News